Prochlorperazine Versus Prochlorperazine & Ketorolac in Treatment of Pediatric Migraine in the Emergency Department
Prochlorperazine Versus Prochlorperazine & Ketorolac in Treatment of Pediatric Migraine in the Emergency Department
The aim of this study is to evaluate whether the use of prochlorperazine and ketorolac in
 combination lead in a larger reduction in pain score compared to prochlorperazine alone when
 treating pediatric migraine in the Emergency Department (ED). Our hypothesis is that this
 combination of medications treats not only the pain but also the associated gastrointestinal
 symptoms of migraine. The main outcome of this study is the reduction in the patient's pain
 score at 60 minutes from administration of the study medications. Secondary outcomes include
 the number of patients achieving complete resolution of the headache while in the ED, the
 number of patients requiring additional treatment interventions by the treating physician,
 the number of patients with resolution of the associated symptoms like nausea, vomiting,
 photophobia and phonophobia, the recurrence of headache in the 48-72 hours after discharge,
 and side effects of the medications.
Inclusion Criteria:

 1. patient aged 8-18 years presenting to Akron Children's Hospital (ACH) ED with
 complaint of headache

 2. patient has an established diagnosis of migraine without aura or as established by
 history meets the criteria for migraine headache as defined by the International
 Criteria for Headache Disorder -II in 2004 a. At least 5 episodes of headache b. The
 headache should last between 1-72 hours c. The headache should include two of the
 following: i. Unilateral location, though may be bifrontal or frontotemporal in
 location but should not be occipital ii. Pulsing quality iii. Moderate to severe pain
 iv. Aggravation by or causing avoidance of routine physical activity d. One of the
 following symptoms should accompany the headache i. Nausea or vomiting ii. Photophobia
 or phonophobia e. The headache should not be attributed to another disorder based on
 history, physical and/or laboratory information.

 Exclusion Criteria:

 1. Patients with a contraindication to receiving prochlorperazine, ketorolac,
 diphenhydramine, or naproxen

 2. Patients unable to complete the pain scale.

 3. Patients on medications that will have a drug-drug interaction with the study
 medication including prochlorperazine, ketorolac, diphenhydramine or naproxen.

 4. Patients with any medical condition that may be contributing or associated with the
 current headache such as concussion or trauma

 5. Female patients with a positive urine HCG point of care test

 6. Patients with diagnosis of or suspected to have chronic daily headaches defined as a
 headache lasting at least 4 hours for more than 15 days a month for the past 3 months.

 7. Patients who received prochlorperazine or ketorolac in the past 48 hours.

 8. Patients who had previously been randomized in this study in the past 3 months.